Triple attack: virus therapy plus two drugs targets liver tumors
NCT ID NCT06283134
First seen Jan 10, 2026 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This early-stage study tests a new treatment for colorectal cancer that has spread to the liver. The treatment combines a modified virus (BioTTT001) with two drugs (toripalimab and regorafenib) to attack the cancer. The main goals are to check safety and find the best dose. About 60 adults who have already tried other treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.